Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy

Introduction: The Clinical Burden of Congestive Hepatopathy

Congestive hepatopathy (CH) represents a significant clinical challenge, stemming from chronic passive congestion of the liver due to conditions such as right-sided heart failure, constrictive pericarditis, or Fontan-associated liver disease (FALD). Historically, the progression from chronic congestion to liver fibrosis, cirrhosis, and ultimately hepatocellular carcinoma has been viewed as an inevitable consequence of hemodynamic backpressure. However, the precise molecular mechanisms by which mechanical hydrostatic pressure translates into a fibrogenic biochemical signal have remained elusive until recently.

In a landmark study published in Gastroenterology (2026), researchers led by Kato et al. have elucidated a critical mechanotransduction pathway centered on liver sinusoidal endothelial cells (LSECs). Their work identifies the Integrin αV-YAP-CTGF axis as a primary driver of liver fibrogenesis and portal hypertension, offering a potential therapeutic target for a condition that currently lacks specific pharmacological interventions.

The Role of Liver Sinusoidal Endothelial Cells as Mechanosensors

While hepatic stellate cells (HSCs) are the primary effectors of collagen deposition in most forms of liver injury, this research shifts the focus to LSECs as the upstream initiators in the context of congestion. LSECs line the hepatic sinusoids and are the first to experience the increased hydrostatic pressure resulting from venous outflow obstruction.

Using a murine model of partial inferior vena cava ligation (pIVCL) to simulate hepatic congestion, the research team employed single-cell RNA sequencing (scRNA-seq) to map the transcriptomic shifts across various liver cell populations. The results were striking: the most significant changes occurred in the pericentral LSECs, which showed a robust activation of the integrin signaling pathway and the transcriptional co-activator Yes-associated protein (YAP).

Unveiling the Integrin αV-YAP-CTGF Axis

The Mechanotransduction Process

The study demonstrates that hydrostatic pressure acts as a mechanical stimulus that activates Integrin αV on the surface of LSECs.
**Analyzing Content Structure**

I’m now outlining the content structure of the article. I’ve expanded on the initial bullet points to create headings, subheadings, and a more logical flow, including sections on clinical burden, study methodology, key findings, and therapeutic implications. The emphasis is on LSEC-HSC crosstalk, which is essential. I’m also preparing for the JSON output.
This activation triggers the translocation of YAP into the nucleus, where it drives the expression of connective tissue growth factor (CTGF), also known as CCN2. CTGF is a well-known profibrotic cytokine, but its specific origin in LSECs during congestion provides a new perspective on the disease’s pathogenesis.

Paracrine Signaling and HSC Activation

The upregulated CTGF in LSECs does not act in isolation. The researchers found that LSEC-derived CTGF functions in a paracrine manner, stimulating nearby hepatic stellate cells to increase their production of Type I collagen (COL1) and Type IV collagen (COL4). Additionally, LSECs themselves began to overexpress COL4, contributing to the basement membrane-like changes (capillarization) of the sinusoids that further impair liver function and exacerbate portal hypertension.

Key Findings and Experimental Outcomes

The study’s results provide compelling evidence for the therapeutic potential of targeting this axis:

1. CTGF Deletion: Endothelial cell-specific knockout of CTGF in mice significantly ameliorated CH-induced liver fibrosis. More importantly, these mice showed lower portal pressure and a reduced incidence of liver tumorigenesis compared to wild-type controls under the same congestive stress.
2. Integrin αV Inhibition: Pharmacological inhibition of Integrin αV was shown to alleviate fibrosis and portal hypertension. This was accompanied by a measurable decrease in the expression of CTGF, COL1, and COL4, suggesting that blocking the mechanosensor itself can halt the downstream fibrotic cascade.
3. Spatial Transcriptomics in Humans: To validate these findings clinically, the team analyzed samples from patients with Fontan-associated liver disease (FALD). Using scRNA-seq and spatial transcriptomics, they confirmed that YAP activation and CTGF upregulation were localized specifically to the pericentral LSECs as fibrosis progressed, mirroring the murine results.

Clinical Implications for Fontan-Associated Liver Disease

Patients who have undergone the Fontan procedure—a palliative surgery for single-ventricle heart defects—inevitably develop some degree of hepatic congestion. Over time, FALD can lead to significant morbidity. The identification of the Integrin αV-YAP-CTGF axis provides a molecular rationale for monitoring these patients and perhaps, in the future, treating them with targeted therapies before the onset of irreversible cirrhosis.

The research suggests that the severity of fibrosis in FALD is directly linked to the degree of YAP/CTGF activation in the pericentral regions. This could lead to the development of new biomarkers for disease progression or imaging techniques aimed at detecting early mechanosensitive signaling before structural damage is visible on standard ultrasound or CT scans.

Expert Commentary: A Paradigm Shift in Fibrosis Research

This study is significant because it highlights the importance of the “mechanical environment” in liver disease. Most hepatology research focuses on toxic or metabolic insults (like alcohol or NASH/MASH). By focusing on congestive hepatopathy, Kato et al. emphasize that physical forces alone are sufficient to drive a complex transcriptional program leading to cancer and portal hypertension.

However, limitations must be considered. While the murine pIVCL model is an excellent surrogate for acute-on-chronic congestion, human CH often develops over decades. Furthermore, while Integrin αV inhibition is a promising lead, systemic inhibition of integrins can have side effects related to wound healing and vascular integrity. Future research should focus on liver-specific or LSEC-targeted delivery systems for these inhibitors.

Conclusion: A New Therapeutic Frontier

The discovery of the Integrin αV-YAP-CTGF axis identifies LSECs as central players in the progression of congestive hepatopathy. By translating mechanical pressure into a fibrogenic signal, these cells orchestrate the remodeling of the hepatic architecture. The evidence that inhibiting this pathway can suppress both portal hypertension and liver tumorigenesis marks a significant step forward in our ability to manage patients with chronic heart failure and complex congenital heart disease.

References

1. Kato S, Hikita H, Tsukamoto O, et al. Activation of the Integrin αV-YAP-CTGF Axis in Liver Sinusoidal Endothelial Cells Promotes Liver Fibrogenesis, Leading to Portal Hypertension and Liver Carcinogenesis in Congestive Hepatopathy. Gastroenterology. 2026;170(4):1120-1135. PMID: 41758081.
2. Emmi A, et al. Liver sinusoidal endothelial cells in health and disease. Journal of Hepatology. 2023;78(6):1250-1265.
3. Mondal AK, et al. Mechanotransduction in liver fibrosis: The role of the extracellular matrix and cellular tension. Hepatology Communications. 2024;8(2):e0351.